explore -WSS

explore

author：fashion 2025-08-12 06:43:09 - browse：97487

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Hilary expected to bring catastrophic, life

WSS

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Listen: More tumult at BIO & coercive care for sickle cell patients

Reports of telehealth's death have been greatly exaggerated

Eyeing GLP

Study finds gene variants tied to breast cancer risk in Black women

As a primary care physician, here's how I hope to partner with AI

hotspot

explore

focus

New air purifier tech could be key to improving indoor air quality

Liver decline slowed by off

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves first treatment for ultra

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Study finds gene variants tied to breast cancer risk in Black women

Anesthesiologist group: stop taking Ozempic before surgery

Patient advocates sound warning on FDA proposal on salt intake

The high cost of giving birth even with insurance

At flashy new research hub, AstraZeneca lays out ambitious growth goals

knowledge

An interview with Robert F. Kennedy Jr. on vaccines

Listen: Racing for gene therapy & a pioneering approval

Study finds gene variants tied to breast cancer risk in Black women

FDA poised to publish guidelines for clinical trial diversity

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Biogen joins immunology wave with $1.15 billion acquisition of HI

entertainment

entertainment

knowledge

focus